[關(guān)鍵詞]
[摘要]
目的 觀察注射用丹參多酚酸治療前循環(huán)急性腦梗死對(duì)患者血清基質(zhì)金屬蛋白酶-9(MMP-9)水平的影響。方法選取2017年1月—2018年12月鄭州市第一人民醫(yī)院治療的112例前循環(huán)急性腦梗死患者,按照1∶1的比例隨機(jī)分配到對(duì)照組和觀察組。對(duì)照組給予缺血性腦血管病基礎(chǔ)治療,觀察組在對(duì)照組治療的基礎(chǔ)上靜脈滴注注射用丹參多酚酸,將0.13 g注射用丹參多酚酸溶于250 mL 0.9%氯化鈉注射液中,1次/d。兩組均以14 d為1個(gè)療程。比較兩組患者治療前、治療7 d及治療14 d后血清MMP-9水平變化情況。結(jié)果 治療7、14 d后,兩組患者血清MMP-9水平均顯著低于治療前,同組治療前后比較差異具有統(tǒng)計(jì)學(xué)意義(P<0.05);且觀察組患者血清MMP-9水平顯著低于對(duì)照組,兩組比較差異有統(tǒng)計(jì)學(xué)意義(P<0.05)。觀察組患者治療14 d后,血清MMP-9水平較治療7 d后有顯著降低(P<0.05)。結(jié)論 注射用丹參多酚酸治療前循環(huán)急性腦梗死患者能夠持久、有效的降低患者血清MMP-9水平,療效確切。
[Key word]
[Abstract]
Objective To observe the efficacy of Salvianolic Acids for injection on MMP-9 levels of anterior circulation acute cerebral infarction patients. Methods A total of 112 patients with anterior circulation acute cerebral infarction in the First People Hospital of Zhengzhou City from January 2017 to December 2018 were randomly divided into control group and observation groups at the ratio of 1: 1. Patients in the control group were received basic treatment, and patients in the observation group were iv administered with Salvianolic Acids for injection on the basis of control group, 0.13 g were added into 0.9% sodium chloride injection 250 mL, once daily. Patients in two groups were treated for 14 d. The serum levels of MMP-9 of patients in two groups were detected at the beginning, 7 and 14 d after treatment, respectively. Results Compared to before treatment, the serum MMP-9 level were significantly decreased after treatment of 7 and 14 d after treatment, the difference was statistically significant (P < 0.05). Comparing with the control group, the serum MMP-9 level in the observation group were decreased significantly at not only the 7th day but also the 14th day after admission, which was statistically significant (P < 0.05). Conclusion Salvianolic Acids for Injection can reduce the serum mmp-9 level of patients with anterior circulation acute cerebral infarction for a long time, and the effect is definite.
[中圖分類(lèi)號(hào)]
R969.4
[基金項(xiàng)目]